SOLNET-GROUP
Solnet Group, a leading provider of smart solar energy solutions for commerce and industry, has released a new report addressing the critical issue of safety in rooftop solar installations. Titled "Safety and Security in C&I Rooftop PV,” the white paper outlines the most important considerations rooftop solar owners and installers can take to minimize risk and protect their investments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115915852/en/
High-quality installers and components reduce risks later (Photo: Business Wire)
According to an audit by Clean Energy Associates, 97% of rooftop solar installations have major safety concerns. Solar panels that are improperly installed or maintained contribute not only to physical safety hazards such as fires but also to power outages and financial losses. A thorough understanding of these risks is necessary as more companies install rooftop solar to mitigate high energy costs and comply with new regulations. Against this backdrop, Solnet Group has compiled a review of risk-reducing technologies and best practices, focusing on how safety can impact the bottom line.
Safety in solar is highly relevant
The revised European Union’s Energy Performance of Buildings Directive will require rooftop solar on all new commercial buildings by 2026, and in renovated commercial buildings by 2027. Beyond this, up to 28% of European companies plan to voluntarily install a solar system within the next 3 years. With rapid growth in the number of solar installations, the risks grow as well. For businesses entering this market, a balance must also be found between upfront installation costs and the long-term operational costs of the array. By considering safety measures from the outset, companies can reduce both risks and costs by minimizing performance issues, keeping insurance premiums low, and mitigating disruptions.
Key findings
1. Safety is a prerequisite for investor confidence: A proactive approach to reducing risk enhances the lifespan of the array and ensures consistent energy generation. In turn, the project generates more value over its lifetime, creating assurance that rooftop solar systems are a viable investment.
2. High-quality installers and components reduce risks later: Comprehensive analyses of solar panel fires from both Germany and the UK indicate that installer error is one of the leading causes of fire incidents, illustrating the importance of a careful installation process. The right components can also mitigate fire risks and other hazards from electrical arcs. Power optimizers, which enable the panel field to be made voltage-free to facilitate firefighting and rescue operations, are increasingly required by insurers as a safety measure in solar installations.
3. Smart monitoring and maintenance tools contribute to a higher safety standard: Real-time monitoring and data analysis tools, coupled with automatic rapid shutdown, allow threats to be addressed right away. As a result, damage is minimized or even avoided, and the operator has a clearer overview of how the system is functioning. The international Zurich Insurance company has recently recommended smart solar systems in part due to the features of their panel-level power optimizers, which can be operated through remote control.
"The rationale behind Solnet’s focus on smart solar technology is not just efficiency; it's about ensuring our solar systems' quality, safety, and longevity. By incorporating features like continuous monitoring and protection mechanisms, we are elevating the safety standards of rooftop solar installations. Our report sheds light on the role of safety improvements in protecting investments and furthering the energy transition," says Arttur Kulvik, SVP Business Development at Solnet Group.
Solnet Group prioritizes safety in every stage of the design, installation, operations, and maintenance of its solar arrays. The company includes power optimizers and a suite of remote monitoring tools, including immediate fault detection alerts, as standard features in its smart solar systems.
The full report is available for download here. Solnet Group will also host a webinar on safety in commercial and industrial rooftop PV, together with representatives from SolarEdge and Zurich Insurance. Registration is open until January 18th.
The speakers at this webinar include Georg Stockschläder, RE Global Practice Leader Property at Zurich Insurance; Chris Voet, Key Accounts Director at Solar Edge; and Arttur Kulvik, SVP Business Development at Solnet Group.
About Solnet Group:
Established in 2014, Solnet Group is a rapidly growing solar energy company with units in the Netherlands, Germany, and Finland. In 2020, the company was listed as the 59th fastest-growing company in Europe on the Financial Times FT1000 list and ranked third in the energy sector. As early as 2016, Solnet Group received the Climate Solver award from WWF. Solnet Group offers comprehensive and high-quality services from consulting and planning to installation throughout Europe. To facilitate our clients' projects, we also provide services for project financing, solar plant maintenance, and repairs. Solnet Group's clientele includes major investment funds, shopping centers, retailers, as well as storage and logistics companies. For more information, visit www.solnet.group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115915852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
